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Atherosclerosis and thrombosis are the 2 major contributing 
mechanisms in coronary artery disease (CAD), a major health 
problem and leading cause of death worldwide. The formation of 
atherosclerotic lesions is augmented by elevated levels of reactive 
oxygen species (ROS).1
Endothelial cell injury is initiated by increased shear stress, 
caused by the combination of high blood viscosity, hypertension 
and vasoconstriction which may be induced by smoking. The 
toxic chemicals present in tobacco smoke affect the endothelium 
and enhance smooth-muscle cell proliferation by inducing platelet 
adherence to damaged cells.2 Nicotine is a strong activator of the 
sympathetic nervous system, which releases catecholamines that 
interfere with haemodynamics, resulting in increased myocardial 
oxygen demand.3 Cigarette smoke contains a complex mixture 
of approximately 4 000 chemical species and plentiful oxygen-, 
nitrogen- and carbon-centred free radicals which increase ROS 
generation and promote oxidative damage.4
Cells produce ROS through normal metabolic processes and 
disruption of the mitochondrial electron transport chain.5 Cell-
intrinsic mechanisms, such as the glutathione (GSH) antioxidant 
defence system, act to combat ROS. Disturbances in the endogenous 
antioxidant defence mechanism or ROS overproduction, however, 
lead to accumulation and availability of free radicals which induce 
oxidative damage to biomolecules by lipid peroxidation, protein 
nitration and DNA adduct formation. 
Cellular detoxification systems protect against endo- and exogenous 
harmful substances. Of particular interest is the super-family of 
glutathione S-transferases (GSTs), which modulate prostaglandin 
signalling pathways and oxidative stress.6 GSTs function to detoxify 
electrophilic toxicants, including those found in cigarette smoke, by 
facilitating conjugation to GSH.7 However, GST function is influenced 
by genotypic differences from single nucleotide polymorphisms (SNPs).8
GST genes contain several polymorphic variants occurring at high 
frequency. In the GSTP1 A105/G105 variant, a single nucleotide change 
from adenine (A) to guanine (G) at codon 105 results in an isoleucine 
(Ile) to valine (Val) amino acid change. In the GSTM1 null (0/0) 
polymorphism, complete deletion of the gene encoding this isoform 
results in abolished enzymatic activity.9 
Several studies assessing genetic susceptibility in response to air 
pollution and cardiovascular outcomes show that GSTP1 and GSTM1 
play a role in ROS modulation.10 Others found an association of 
GSTM1 0/0 with heart failure.11,12 Black carbon and particulate matter 
exposure was shown to be associated with increased intracellular and 
vascular cell adhesion molecules, which promoted atherosclerosis; 
this association was modified by the presence of the GSTM1 
polymorphism.13 GSTP1 and GSTM1 polymorphisms have been 
associated with the biomarker of oxidative DNA damage, 8-hydroxy-
2’-deoxyguanosine and increased susceptibility to smoking-related 
CAD.14,15-17
The high incidence of CAD in South Africans of Indian ancestry 
in Durban was reported in 1969.18 More than 40 years later, 
epidemiological data in South Africa (SA) showed Indians to have the 
highest mortality rates for CAD, followed by mixed race, white and 
black.19 Recent studies show a strong familial link with the history of 
diabetes mellitus type 2, hypertension and CAD, supporting a genetic 
basis for development.20,21 
In light of the evidence that variants of GSTP1 and GSTM1 influence 
disease risk, we assessed the association of GST polymorphisms 
in young smoking and non-smoking South African Indian CAD 
patients.
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Background. Glutathione S-transferases (GSTs) detoxify 
environmental agents which influence the onset and progression 
of disease. Dysfunctional detoxification enzymes are responsible 
for prolonged exposure to reactive molecules and can contribute 
to endothelial damage, an underlying factor in coronary artery 
disease (CAD). 
Objectives. We aimed to assess 2 common polymorphic variant 
isoforms in GSTM1 and GSTP1 of GST in young CAD patients. 
Methods. All patients (N=102) were South Africans of 
Indian ancestry, a population associated with high CAD risk. A 
corresponding age-, sex- and race-matched control group (N=100) 
was also recruited. Frequency of the GSTM1 +/0 (v. +/0 and 0/0) 
and GSTP1 A105/G105 (v. wild-type A105/A105) genotypes was assessed 
by differential polymerase chain reaction (PCR) and PCR restriction 
fragment length polymorphism (PCR-RFLP), respectively.
Results. The GSTM1 0/0 and GSTP1 A105/A105 genotypes 
occurred at higher frequencies in CAD patients compared with 
the control group (36% v. 18% and 65% v. 48%, respectively). 
A significant association with CAD was observed in GSTM1 
0/0 (odds ratio (OR)=2.593; 95% confidence interval (CI) 1.353 
- 4.971; p=0.0043) and GSTP1 A105/A105 OR=0.6011; 95% CI 
0.3803 - 0.9503; p=0.0377). We found a significant association 
between smoking and CAD; the presence of either of the respective 
genotypes together with smoking increased the CAD risk (GSTP1 
A105 relative risk (RR)=1.382; 95% CI 0.958 - 1.994; p=0.0987 and 
GSTM1 null RR=1.725; 95% CI 1.044 - 2.851; p=0.0221). 
Conclusion. Our findings support the association of genotypes 
GSTM1 0/0 and GSTP1 A105/A105 and smoking with CAD.
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Methods
A total of 102 young Indian CAD patients and 100 age-, race- and 
sex-matched controls were enrolled following institutional ethical 
approval (BE154/010). A full pathology report was compiled. The 
inclusion criterion for CAD patients were: Indian ancestry and 
unrelated, adults aged <45 years, and stable CAD confirmed at 
angiography. The exclusion criteria for controls included an acute 
coronary syndrome/revascularisation procedure in the preceding 3 
months, chronic renal or liver disease, malignancy and known active 
inflammatory or infectious disease. 
Genomic DNA was extracted from whole blood. Cells were 
transferred to 500 µl lysis buffer (0.5% sodium dodecyl sulphate 
(SDS), 150 mM NaCl, 10 mM ethylenediaminetetra-acetic acid 
(EDTA), 10 mM Tris-HCl (pH 8.0)). RNase A (100 µg/ml; DNase-
free) was added and the mixture incubated (37°C, 1 h). Subsequently, 
proteinase K (200 µg/ml) was added and incubated (3 h, 50°C) 
and a 0.1% volume 5 mM potassium acetate was added before 
centrifugation (5000 xg; 15 min). Supernatants containing genomic 
DNA were transferred to fresh tubes and extracted with 100% 
isopropanol and washed with 70% ethanol. DNA samples were 
solubilised in 10 mM Tris and 0.1 mM EDTA (pH 7.4, 4°C). DNA 
concentration was determined spectrophotometrically. 
Differential polymerase chain reaction (PCR) was performed to 
assess the GSTM1 polymorphism: 268 base pair (bp) (β-globin) and 
215 bp (GSTM1) PCR products were amplified using 30 pmol of 
primers for the GSTM1 gene and 10 pmol primers for the β-globin 
gene in a 25 μl reaction (200 μM of each deoxyribonucleotide 
(dNTP), 3.3 mM MgCl2, 1x Green GoTaq Flexi buffer, 1 U GoTaq 
DNA polymerase (Promega), 100 ng genomic DNA template). Primer 
sequences: GSTM1-Fwd 5’-GAACTCCCTGAAAAGCTAAAGC-3’; 
GSTM1-Rev 5’-GTTGGGCTCAAATATACGGTGG-3’; β-globin-
Fwd 5’-CAACTTCATCCACGTTCACC-3’; β-globin-Rev 
5’-GAAGAGCCAAGGACAGGTAC-3’. Following denaturation 
(96°C, 5 min), amplification was carried out with 25 cycles of 
denaturation (96°C, 30 sec), annealing (57°C, 30 sec) and extension 
(72°C, 30 sec), followed by a final extension (72°C, 5 min). 
Amplification products were electrophoresed on an agarose gel (4%, 
0.5 mg/ml ethidium bromide) and visualised. The presence of a single 
268 bp product was indicative of the homozygous null genotype. The 
amplification of a 215 bp product was indicative of the presence of the 
gene in either a homozygous positive or heterozygous state. 
PCR-restriction fragment length polymorphism (PCR-
RFLP) was used to determine the GSTP1 genotype. A 176 
bp PCR product was amplified using 15 pmol of each primer 
(forward 5’-ACCCCAGGGCTCTATGGGAA-3’ and reverse 
5’-TGAGGGCACAAGAAGCCCCT-3’) in a 25 μl reaction 
containing 200 μM of each dNTP, 2.5 mM MgCl2, 1x Green GoTaq 
Flexi buffer, 0.5U GoTaq DNA polymerase and 100 ng genomic 
DNA template. Following initial denaturation (96°C, 5 min), 
amplification was carried out with 30 cycles of denaturation (96°C, 
30 sec), annealing (55°C, 30 sec) and extension (72°C, 30 sec). 
This was followed by a final extension (72°C, 5 min). Presence 
of the polymorphic restriction site was analysed by restriction 
endonuclease digestion of the PCR amplicon. Overnight digestion 
(37°C) was performed in 25 μl reactions: 15 μl PCR product, 
4.5 μl Buffer-R and 0.5 μl (5 U) BsmAI (Fermentas). Amplicons 
homozygous for the G105 allele were completely digested and 
resulted in 2 restriction fragments (91 bp and 85 bp). Restriction 
fragments were electrophoresed on an agarose gel (3%, 0.5 mg/ml 
ethidium bromide) and visualised.
Statistical analyses were performed with GraphPad Prism software 
(version 5.0). 
Results 
Among the clinical parameters assessed between the groups, body 
mass index (BMI), hypertension, diabetes, triglycerides, fasting 
glucose and HbA1c were higher in patients than in controls (Table 
1). Single nucleotide changes at codon 105 of the GSTP1 gene were 
investigated using RFLP-PCR. The genotype frequencies observed 
did not deviate from those predicted by Hardy-Weinberg statistics 
(GSTP1: p=0.294 in CAD patients, p=0.413 in controls; GSTM1 
p=0.083 in CAD patients, p=0.64 in controls; chi-square test). 
A significant skew towards frequency of the A105/A105 genotype 
was observed in CAD patients compared with the controls. In the 
control group, the homozygous A105/A105 and heterozygous A105/G105 
genotypes were observed at frequencies of 48% and 45%, respectively. 
The frequency of the A105/A105 genotype was significantly higher in 
CAD patients (65% v. 48%, respectively; odds ratio (OR)=0.6011, 95% 
confidence interval (CI) 0.3803 - 0.9503, p=0.0377; Table 2). GSTM1 
0/0 was also significantly more frequent in CAD patients (36% v. 18%; 
OR=2.593, p=0.0043; Table 3) compared with +/+ and +/0 genotypes.
A higher frequency of the GSTP1 A105 and GSTM1 null alleles was 
observed in patients; therefore, we investigated whether there were 
genotypic differences in relative CAD risk in respect of these loci. Our 
findings suggest that the presence of either of these genotypes confers 
a significant CAD risk (Table 2). We stratified the groups according 
to smoking history: the number of smokers in the patient group was 
much higher than in the control, with a significant association between 
smoking and CAD (p<0.0001, OR=0.2245, 95% CI 0.1062 - 0.4746). 
Most smokers presented with GSTP1 A105/A105 (p=0.0987, OR=0.5667, 
95% CI 0.2952 - 1.088; Table 4) and GSTM1 0/0 (p=0.0221, OR=2.386 
95% CI .137 - 5.009; Table 4). The higher relative risk of CAD associated 
with these genotypes is increased with smoking. 
Discussion
The INTERHEART study ranked smoking as the second highest 
risk factor for myocardial infarction (OR=2.87, 99% CI).22 The 
Systemic Coronary Risk Evaluation project estimated the 10-year 
fatal cardiovascular risk to be twice as high for smokers v. non 
smokers for any given age, systolic BP and cholesterol level.23 The 
number of smokers worldwide is expected to reach 1.7 billion by 
2025.24,25 With current trends, smoking-related deaths are expected to 
rise from 4.8 million in 2000 to 8 million in 2030.25 
Endothelial cell damage in vasculature is caused by changes 
in haemodynamics and oxidative stress, leading to thrombosis 
and atherosclerosis. The continuous cycle of inflammation from 
atherosclerotic plaques and arterial wall lesions contributes to elevated 
levels of C-reactive protein in CAD. The low-grade inflammation, 
recruitment and activation of leucocytes to the atherosclerotic 
lesion plays an important role in ROS generation in an attempt to 
circumvent the spread of foreign material, while simultaneously 
exposing biomolecules to oxidative stress.5
Our data show an association of wild-type GSTP1 A105/A105 and 
GSTM1 0/0 with CAD. The presence of allele GSTP1 G105 in the 
healthy control patients signals a possible role of this polymorphism 
in enhancing the efficacy of antioxidant mechanisms. GST acts 
as a general base catalyst, increasing the rate of GSH conjugation 
to hydrophobic substrates by deprotonation to GS- by an active 
tyrosinate. The change in codon 105 of the GST gene results in an 
amino acid substitution from Ile to Val. This was previously shown 
to cause deviations in the atomic co-ordinates of key H-site residue 
side-chains, thereby altering GST catalytic ability and increasing 
susceptibility to smoking-related CAD.15-17 Earlier literature, however, 
indicates 7 times more active conjugation to diol epoxides and 
increased catalytic efficiency to aromatic epoxides.8 
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GSTM1 0/0 results in complete absence of the enzyme isoform, 
which affects detoxification capacity. The strong association of this 
genotype in CAD patients indicates a key role in disease pathogenesis. 
The association between smoking and CAD in this cohort is in 
agreement with previous studies.15-17 The high percentage of patients 
who smoked and presented with GSTP1 A105/A105 and GSTM1 0/0 
supports the hypothesis that GSTs play an important role in CAD.
Study limitations included sample size, lack of exclusion criteria 
based on body mass index (BMI), hypertension and diabetes.
Conclusion
This study provides evidence that the GSTP1 A105 allele and the 
GSTM1 null genotype are associated with CAD in young South 
Africans of Indian ancestry.
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Non-smokers 35 (35) 11 (10) p<0.0001
RR=1.826
95% CI (1.427 - 2.336)Smokers/ex-smokers 65 (65) 91 (90)
Smokers/ex-smokers GSTP1 A105/G105 and G105/G105 31 (31) 31 (30) p=0.0987
RR=1.382
95% CI (0.958 - 1.994)GSTP1 A105/A105 34 (34) 60 (59)
GSTM1 +/+ and +/0 52 (52) 57 (56) p=0.0221
RR=1.725
95% CI (1.044 - 2.851)GSTM1 0/0 13 (13) 34 (33)
RR = relative risk; CI = confidence interval.
